NCT04575116View on ClinicalTrials.gov

A Study to Determine the Bioequivalence of Two Doses of Tafamidis

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

February 23, 2021

Study Completion Date

February 23, 2021

Conditions
Healthy
Interventions
DRUG

Tafamidis free acid tablet

12.2 mg tafamidis free acid tablet

DRUG

Tafamidis meglumine capsule

20 mg tafamidis meglumine soft gelatin capsule

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY